Close Menu

University of New Mexico

The company will test samples from women treated with an investigational combination of AstraZeneca's PARP inhibitor olaparib and immunotherapy tremelimumab.

The institutes will lead a consortium of researchers investigating the molecular underpinnings of diabetic retinopathy, a key cause of blindness.

The firm's assay is designed to detect the relative abundance of bacteria species in a patient's sample, allowing doctors to improve long-term inpatient care decisions.

Armonica Technologies is looking to develop a nanochannel-based sequencing device that uses optical detection. 

In Science this week: convergent evolution in bird hemoglobin, and more.

The technique will use optical maps and barcodes in order to generate long scaffolds from short-read sequencing technology.

The funding will support work identifying the mechanisms underlying the differential responses among pediatric and adult ALL patients to therapy.

NEW YORK (GenomeWeb News) – Life Technologies has added 11 new members from the US and Canada to its Ion AmpliSeq Exome Certified Service Provider program, the company said today.

This story was originally published on Sept. 21.

An international research team genotyped more than 2,000 cervical cancers in New Mexico and investigated how different HPV genotype patterns were linked to cervical cancers, age of diagnosis, and more.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.